The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
Official Title: Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
Study ID: NCT02724540
Brief Summary: The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California San Francisco, San Francisco, California, United States
Stanford University, Stanford, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Mount Sinai School of Medicine, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Oregon Health & Science University, Portland, Oregon, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Hospital Italiano de Buenos Aires, Buenos Aires, , Argentina
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Ospedale San Raffaele, Milan, , Italy
Name: Michael C Soulen, MD, FSIR
Affiliation: University of Pennsylvania
Role: PRINCIPAL_INVESTIGATOR